Insulet Corporation (NASDAQ:PODD) is one of the most promising healthcare stocks according to Wall Street analysts.
On June 6, Insulet Corporation (NASDAQ:PODD) released new clinical results for two of its next-generation diabetes management systems, which management described as strong and that bring the company closer to making the systems a reality
Cherries/ The two diabetes systems are Omnipod 6 and a fully closed-loop (FCL) system for type 2 diabetes. In the first study, dubbed STRIVE pivotal trial, the company compared the current Omnipod 5 with Omnipod 6 and found that the latter improved time in tight range by 7% for type 1 adults and by 5% for type 2 patients. Overall time in range also improved across both groups.
The results also show that the new system delivered up to 50% more automated insulin. Another key finding from STRIVE was that Omnipod 6 performed far better even when patients bolused less. The company explained that this matters because one of the biggest reasons people with diabetes don’t hit their targets is inconsistency in remembering or choosing to manually dose for meals.